So far, genetic changes of BHLHE41/DEC2 have not been studied well; however, GEPIA (http://gepia.cancer-pku.cn/) (accessed on 6 July 2023) indicates high expression of BHLHE41/DEC2 in ovarian serous adenocarcinoma (OV), stomach adenocarcinoma (STAD), thyroid cancer, ccRCC, and so on. Here, BHLHE41 is linked to ovarian serous adenocarcinoma.